Open-house discount agreements for biologic medicines 2026–32: aflibercept

Summary

Participating health insurance funds intend to conclude discount agreements with all suitable pharmaceutical companies for the active substance aflibercept. The agreements will cover the lots specified individually in the tender documents and will run for a maximum of 24 months, starting on 1 January 2027; the VIACTIV health insurance fund’s contract starts on 1 December 2027. All agreements end no later than 31 December 2028, regardless of when they are concluded.